Pharma channel feed – Endpoints News

Pharma channel feed

Bristol-Myers wins the frenzied race to a first approval for a PD-1/L1 checkpoint in China as regulators hustle up a quick OK

8 years ago

Nightstar's drug for rare vision loss admitted to FDA's gene therapy speedway

8 years ago

GSK wins yet another reprieve for blockbuster Advair franchise as Mylan is hit (again) with a CRL

8 years ago

On a roll, Sage grabs a $575M deal on limited Asian rights to SAGE-217 — a potential gamechanger in depression

8 years ago

Blame the ozanimod fiasco on the Receptos team? Just wait a sec, says ex-CEO, who sold the company to Celgene for $7.2B

8 years ago

This extravagant party during #BIO18 featured topless dancers, and industry leaders are not pleased

8 years ago

UK bank launches £2.5B plan to fund innovation, with a special place for its long-ailing biotech scene

8 years ago

Stepping into the pricing debate, FDA chief Scott Gottlieb proposes new reimbursement idea for antibiotics

8 years ago

With a big assist from the FDA, Sage plots a swift march through PhIII for oral depression drug -- market cap swells $1B-plus

8 years ago

Novartis hands Regenxbio $100M in fast cash for vector tech

8 years ago

Gene editing stocks get bushwhacked as new studies highlight CRISPR/Cas9 cancer risks

8 years ago

Alexion cautiously steps over to the C6 pathway with an early-stage development deal tied to buyout option

8 years ago

Sanofi builds on mRNA alliances with an $805M pact for Ron Renaud’s Translate Bio

8 years ago

AbbVie, Roche post a big win with a blockbuster FDA OK for Venclexta/Rituxan combo for leukemia

8 years ago

Visualize: ASCO 2018's winners and losers

8 years ago

Diabetes giant Novo said to consider up to 3,000 layoffs as US pricing storms gather: report

8 years ago

Relocating its US HQ to Boston, French pharma Ipsen to add 250 jobs

8 years ago

Gates Foundation sets up biotech-like institute in hands-on effort to spur drug development for neglected diseases

8 years ago

That big Biogen deal you were waiting for? Keep waiting

8 years ago

Mega-blockbuster? Pfizer lines up for a snap review of its PARP drug talazoparib — and a launch into a crowded market

8 years ago

Genentech dives deeper into the microbiome, inking $534M deal with Microbiotica to develop IBD meds

8 years ago

Picking up the pieces left from an Alzheimer’s implosion, Axovant is starting over by diving into gene therapy

8 years ago

Gilead ups its bet on HIV, hep B, inking $400M partnership with immunotherapy company Hookipa

8 years ago

With competition on its heels, Blueprint takes three cancer drugs to China

8 years ago

First page Previous page 301 302 303304305 306 307 Next page Last page